课题基金 / 基金详情

Release Chondroitinase Systems for Spinal Cord Injury

Release Chondroitinase Systems for Spinal Cord Injury
释放软骨素酶系统治疗脊髓损伤
批准号:
6689094
负责人:
ANTHONY O CAGGIANO
金额:
$10.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2004-02-29

项目摘要

项目成果

ANTHONY O CAGGIANO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and causes a severe and debilitating condition in the individual. Following SCI, limited regeneration of injured neurons results in permanent disability characterized by some loss of sensation, paralysis and autonomic dysfunction. One reason that neurons fail to regenerate is their inability to traverse the glial scar that develops following SCI. This glial scar contains extra cellular matrix molecules including chondroitin sulfate proteoglycans (CSPGs). In vitro studies show that neurons fail to extend processes over CSPG coated surfaces, while in vivo data correlate failure of regeneration with areas of CSPG expression. Treatment with bacterial chondroitinase (Chase), an enzyme that digests CSPG arbohydrate chains, decreases the CSPG inhibition, both in vitro and in vivo. Chase was recently used to treat spinal cord lesions in a rodent model, resulting in enhanced functional recovery. Several obstacles exist in the development of a Chase-based SCI therapy, including the delivery of a large protein to the central nervous system and the use of an enzyme with a short half-life in solution at body temperature. The aim of this study is to develop a sustained release (SR) formulation of a Chase therapy that can be delivered locally to the site of injury and demonstrate its effectiveness at digesting CSPGs in the rat spinal cord. To accomplish these goals are a repertoire of Chase enzymes will be cloned, expressed and purified. These enzymes will then be tested in vitro in several existing sustained release formulations. These sustained release Chase formulations will then be place in the sub-dural space of rat spinal cords to assess their ability to digest CSPGs in vivo. These studies will provide justification for a Phase II study examining the therapeutic effects of sustained release formulation of chondroitinase in an animal model of spinal cord injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
  • 批准号:
    10674687
  • 项目类别:
  • 资助金额:
    $847.91万
  • 财政年份:
    2021
  • 负责人:
    ANTHONY O CAGGIANO
  • 依托单位:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
  • 批准号:
    10187183
  • 项目类别:
  • 资助金额:
    $1076.47万
  • 财政年份:
    2021
  • 负责人:
    ANTHONY O CAGGIANO
  • 依托单位:
Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease
  • 批准号:
    10247968
  • 项目类别:
  • 资助金额:
    $164.28万
  • 财政年份:
    2021
  • 负责人:
    ANTHONY O CAGGIANO
  • 依托单位:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies
  • 批准号:
    10402396
  • 项目类别:
  • 资助金额:
    $1025.43万
  • 财政年份:
    2021
  • 负责人:
    ANTHONY O CAGGIANO
  • 依托单位:
海外基金